Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 6, 2010, Pages 707-714

  Wade, Derick T ^a   Collin, Christine ^a   Stott, Colin ^a   Duncombe, Paul ^a  

^a OXFORD CENTRE FOR ENABLEMENT   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoids; Delta 9 tetrahydrocannabinol; Multiple sclerosis; Nabiximols; Sativex; Spasticity

Indexed keywords

CANNABINOID; CANNABIS; NABIXIMOLS; PLACEBO; UNCLASSIFIED DRUG; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

AGED; ARTICLE; BREAST DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SKIN DISEASE; SPASTICITY; SUBCUTANEOUS FAT DISORDER; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VASCULAR DISEASE; VISUAL ANALOG SCALE; VOMITING; ADULT; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; MUSCLE SPASTICITY; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN MEASUREMENT; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953796878     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510367462     Document Type: Article

References (23)

1. Shakespeare DT, Boggild M., Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003 ; 4: CD001332.
2. Beard S., Hunn A., Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003 ; 7 (40). iii, ix - x, 1-111.
3. Wade DT, Robson P., House H., Makela P., Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003 ; 17: 21-29.
4. Wade DT, Makela P., Robson P., House H., Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004 ; 10: 1-8.
5. Wade DT, Makela PM, House H., Bateman C., Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006 ; 12: 639-645.
6. Collin C., Davies P., Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007 ; 14: 290-296.
7. Collin C., Ehler E., Waberzinek G., et al. A double-blind, randomised, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010 ; DOI: 10.1179/ 016164109X12590518685660.
8. Zajicek J., Fox P., Nunn A., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet (North American Edition) 2003 ; 362: 1517-1526.
9. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005 ; 76: 1664-1669.
10. Vaney C., Heinzel-Guttenbrunner M., Jobin P., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004 ; 10: 417-424.
11. Lance JW Symposium synopsis. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Chicago: Chicago Year Book Publishing Co, 1980, p. 485-495.
12. Pandyan A., Johnson G., Price C., Curless R., Barnes M., Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 1999 ; 13: 373-383.
13. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964 ; 192: 540-542.
14. Morris S. Ashworth and Tardieu scales; their clinical relevance for measuring spasticity in adult and paediatric neurological populations. Phys Ther Rev 2002 ; 7: 53-62.
15. Fleuren JFM, Voerman GE, Erren-Wolters CV, et al. Stop using the Ashworth Scale for the Assessment of Spasticity. J Neurol Neurosurg Psychiatry 2010 ; 81: 46-52.
16. Bohannon RW, Smith MB Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987 ; 67: 206-207.
17. Brown MB, Forsythe AB Robust Tests for Equality of Variances. JAMA 1974 ; 69: 364-367.
18. Farrar J., Troxel A., Stott C., Duncombe P., Jensen P. Validity, reliability, and clinical importance of change in a 0-10 Numeric Rating Scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008 ; 30: 974-985.
19. Whitehead A., Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 1991 ; 10: 1665-1677.
20. Farrar JT, Young Jr JP, LaMoreaux L., Werth JL, Poole RM Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001 ; 94: 149-158.
21. Anwar K., Barnes M. A Pilot Study of a Comparison Between a Patient Scored Numeric Rating Scale and Clinician Scored Measures of Spasticity in Multiple Sclerosis. NeuroRehabilitation 2009 ; 24: 333-340.
22. Pandyan AD, Gregoric M., Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005 ; 27: 2-6.
23. Altman DG Personal communication.